Biotech Values

[DewDiligence]

Thank you for the overview of the VDA arena. This excerpt caught my attention:

“Data from a Phase Ib trial with CA4P plus the approved VEGF inhibitor Avastin… should become known in the third quarter of this year, and positive results would lead to a Phase II study testing a quadruplet combo regimen against NSCLC in the second half.”

I’m going to go out on a limb and predict that this quadruplet regimen (Avastin + CA4P + dual chemo) will prove to be too toxic, and that such a regimen will never be used commercially. Regards, Dew

p.s. jbog: Do you agree?